Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.71K Sell
362
-146
-29% -$3.82K ﹤0.01% 576
2026
Q1
$14.3K Buy
+508
New +$13.5K ﹤0.01% 483
2025
Q4
Sell
-613
Closed -$15.6K 451
2025
Q3
$15.6K Buy
613
+127
+26% +$3.13K ﹤0.01% 449
2025
Q2
$11.8K Sell
486
-1,317
-73% -$30.7K ﹤0.01% 465
2025
Q1
$45.7K Buy
1,803
+821
+84% +$21.5K 0.02% 259
2024
Q4
$26K Sell
982
-476
-33% -$12.9K 0.01% 351
2024
Q3
$42.2K Buy
1,458
+171
+13% +$4.99K 0.02% 285
2024
Q2
$36.2K Sell
1,287
-1,490
-54% -$41K 0.02% 307
2024
Q1
$77K Buy
2,777
+1,723
+163% +$47.8K 0.03% 225
2023
Q4
$30.4K Buy
+1,054
New +$31.9K 0.01% 523

Other funds holding PFE

Main Street Group's PFE Position: Q2 2026 in Review

Main Street Group reduced its Pfizer (PFE) stake by 29% in Q2 2026, selling an estimated $3.82K and leaving 362 shares worth $8.71K. The position accounts for ﹤0.01% of the portfolio, ranked #576.

Main Street Group first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. The position peaked at $77K in Q1 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Main Street Group held 362 shares of Pfizer worth $8.71K as of Q2 2026.
  • Main Street Group sold 146 Pfizer shares in Q2 2026, an estimated $3.82K.
  • Pfizer made up ﹤0.01% of Main Street Group's portfolio in Q2 2026, its #576 holding.
  • Main Street Group first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • Main Street Group's Pfizer position peaked at $77K in Q1 2024.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Main Street Group's 13F filing for Q2 2026, filed 13 Jul 2026.